Cytokinetics' Aficamten Shows Stronger Exercise Benefits in Non-Obstructive HCM

  • Cytokinetics presented additional ACACIA-HCM trial data at HFSA 2026, showing aficamten significantly improved exercise performance in non-obstructive HCM patients.
  • 53% of aficamten-treated patients showed clinical response in three or more domains vs. 13% on placebo.
  • Cytokinetics plans to submit a supplemental New Drug Application to the FDA this quarter.
  • 10.5% of aficamten patients experienced LVEF <50%, with most heart failure events occurring during dose titration.

Cytokinetics' positive ACACIA-HCM data positions aficamten as a potential first-line treatment for non-obstructive HCM, a market currently underserved by approved therapies. The company's ability to navigate regulatory scrutiny and commercialize the drug effectively will determine its long-term competitive position in the cardiovascular space. With approximately half of HCM patients classified as non-obstructive, a successful approval could significantly expand Cytokinetics' revenue potential.

Regulatory Timeline
Whether the FDA will approve aficamten for non-obstructive HCM by mid-2027, given the strong efficacy data but safety concerns around heart failure risk.
Market Expansion
How Cytokinetics will position aficamten against existing treatments for non-obstructive HCM, potentially expanding its addressable market.
Safety Monitoring
The pace at which Cytokinetics can refine dosing protocols to minimize heart failure risks while maintaining efficacy.